Portland’s UbiVac To Brief International Immuno-Oncology Forum in Chicago

FOR IMMEDIATE RELEASE

June 2, 2016

Contact: Patricia Pearson, ppearson@the3wgroup.com   503.887.1871


Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2nd Annual 2016 Sachs Immuno-Oncology BD&L and Investment Forum on June 3 in Chicago.

During his remarks, Dr. Fox will detail UbiVac’s DRibble immunotherapy (DPV-001), a first in class technology that combines more than 100 cancer targets including at least 13 National Cancer Institute (NCI) prioritized cancer antigens. Ongoing Phase II clinical trials confirm that DRibble technology is novel and can help induce immunity against cancer.

UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy, and fills a gap in the pipeline of major pharmaceutical companies currently developing immuno-oncology therapies. DPV-001 is currently being evaluated in an NCI-supported, randomized, multi-center Phase II clinical trial.

Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). “We are excited to report early results documenting DPV-001’s ability to  educate the immune systems of patients so they can recognize their cancer,” Dr. Fox said.

UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open for patients with breast cancer.

Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.

The Sachs Immuno-Oncology: BD&L and Investment Forum, www.sachsforum.com brings together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. According to organizers, the one-day meeting is expected to draw about 250 delegates and will include 30 presentations by both listed and private biotechnology companies.

Sachs Associates is considered to have significant knowledge of key individuals operating within the European and global biotech field and, through this annual Forum, provides an effective platform for companies like UbiVac to gain recognition among research collaborators and funders.


About UbiVac

UbiVac is a clinical stage immuno-oncology company engaged in research and development of therapeutic immunotherapies to combat cancer. Founded in Portland, Ore. In 2005, it is a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with other research partners. The company’s co-founder, president and CEO, Bernard A. Fox, PhD, holds the Harder Family Endowed Chair for Cancer Research and is member and Chief, Laboratory of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center.

Bernie Fox